Belgium· BE-AMP-SAM179462-00
Accolate-20 20 mg
A zafirlukast product containing zafirlukast, registered in Belgium by AstraZeneca. The same ATC class is registered in 5 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Zafirlukast is registered in 5 of 19 countries.
Countries holding a registration under ATC R03DC01 (zafirlukast), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 4 of them publish a price we can compare per daily dose
Zafirlukast · ATC R03DC01
5 / 19 countries
- Belgiumprice
- Finlandprice
- Norwayprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Zafirlukast
- Manufacturer
- AstraZeneca
- Country
- Belgium (BE)
- ATC code
- R03DC01
- ATC class
- Zafirlukast
- Defined daily dose
- 40 mg, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb1265420
- be_apb0749879
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
459 interactions on record for zafirlukast.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Zafirlukast · interactions on record
459 records
- 15 severe
- 265 moderate
- 20 minor
- 159 info
Most severe, free to view
- LonafarnibA16AX20severe
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- PexidartinibL01EX15severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Zafirlukast in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8b37ffd9-2637-4e0c-abbd-530ee69e8155 GET /v1/drugs/8b37ffd9-2637-4e0c-abbd-530ee69e8155?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"source": "afmps",
"status": "REVOKED",
"name_en": "Accolate-20 20 mg",
"name_fr": "Accolate-20 20 mg",
"name_nl": "Accolate-20 20 mg",
"amp_code": "SAM179462-00",
"strengths": [
"20.0000",
"20.0000"
],
"pack_count": 2,
"substances": [
"Zafirlukast"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Zafirlukast",
"authorisation_numbers": [
"BE179462"
]
}See everything about zafirlukast.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.